The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
EMT is the dominant program in human colon cancer
Open accessAbstract
Background: Colon cancer has been classically described by clinicopathologic features that permit the prediction of outcome only after surgical resection and staging. Methods: We performed an unsupervised analysis of microarray data from 326 colon cancers to identify the first principal component (PC1) of the most variable set of genes. PC1 deciphered two primary, intrinsic molecular subtypes of colon cancer that predicted disease progression and recurrence. Results: Here we report that the most dominant pattern of intrinsic gene expression in colon cancer (PC1) was tightly correlated (Pearson R = 0.92, P < 10-135) with the EMT signature-- both in gene identity and directionality. In a global micro-RNA screen, we further identified the most anti-correlated microRNA with PC1 as MiR200, known to regulate EMT. Conclusions: These data demonstrate that the biology underpinning the native, molecular classification of human colon cancer--previously thought to be highly heterogeneous-- was clarified through the lens of comprehensive transcriptome analysis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



![Figure 4 Covariance matrix showing correlation of PC1 with disease recurrence. (a) PC1, despite being developed with unsupervised approaches, appeared to correlate well with EMT, disease recurrence, disease progression, and differentiation status, but not with gene signatures linked to adenoma vs. carcinoma, MSI status, or mucinous vs. nonmucinous cancers. Moreover, PC1 appeared to be anti-correlated with RAS, MYC, Proliferation, and colon laterality. PC1 distinguishes good and poor prognosis patients in the MCC data set (b) as well as in two independent test sets: (c) Netherlands Cancer Institute (NKI, #13) (L.V.V.) and (d) Lin et al data sets [21].](https://figures.cochat.ai/paper-figures/6c580ff83bab49188a53a2626fb9c65b/emt-is-the-dominant-program-in-human-colon-cancer-figure-4.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“supporting the notion that EMT is arguably the dominant program in human CRC [25]”
From An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy (2022) · cites this paper as [25]
The cited source says what the claim attributes to it.
In the citing paper
“Now our new analysis in 2250 CRC tumors confirmed this tight correlation between EMT and PC1 signature scores (Spearman r = 0.92, P < 10–320, Fig. 3a), supporting the notion that EMT is arguably the dominant program in human CRC [25].”
From An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy (2022) · cites this paper as [25]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Gregory, P. A., Bert, A. G., Paterson, E. L., Barry, S. C., Tsykin, A., Farshid, G., Vadas, M. A., Khew-Goodall, Y., & Goodall, G. J. (2008) · Nature Cell Biology · doi:10.1038/ncb1722 · Cited by 3,863 · cited 1×
“It has been previously demonstrated that MiR 200 over-expression may result in inhibition of ZEB1/2, which in turn leads to inhibition of transcriptional repressors of CDH1, thereby permitting the expression of CDH1 and expression of the epithelial phenotype [26,27].”
BackgroundPark, S.-M., Gaur, A. B., Lengyel, E., & Peter, M. E. (2008) · Genes & Development · doi:10.1101/gad.1640608 · Cited by 2,272 · cited 1×
“It has been previously demonstrated that MiR 200 over-expression may result in inhibition of ZEB1/2, which in turn leads to inhibition of transcriptional repressors of CDH1, thereby permitting the expression of CDH1 and expression of the epithelial phenotype [26,27].”
BackgroundOncogenic pathway signatures in human cancers as a guide to targeted therapies
Bild, A. H., Yao, G., Chang, J. T., Wang, Q., Potti, A., Chasse, D., Joshi, M.-B., Harpole, D., Lancaster, J. M., Berchuck, A., et al. (2006) · Nature · doi:10.1038/nature04296 · Cited by 2,032 · cited 1×
“MYC and RAS signatures were obtained from Nevins et al [16,17].”
MethodEdwards, B. K., Ward, E., Kohler, B. A., Eheman, C., Zauber, A. G., Anderson, R. N., Jemal, A., Schymura, M. J., Lansdorp‐Vogelaar, I., Seeff, L. C., et al. (2010) · Cancer · doi:10.1002/cncr.24760 · Cited by 2,002 · cited 1×
“Analysis of other cancers such as pancreas and lung demonstrate a spectrum of EMT across diseases (colon < lung < pancreas) that may explain the differential survivability of these cancers (colon > lung > pancreas), variable recurrence rates, and responses to therapy [31].”
BackgroundDesmedt, C., Piette, F., Loi, S., Wang, Y., Lallemand, F., Haibe-Kains, B., Viale, G., Delorenzi, M., Zhang, Y., d'Assignies, M. S., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2765 · Cited by 968
Singh, A., Greninger, P., Rhodes, D., Koopman, L., Violette, S., Bardeesy, N., & Settleman, J. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.022 · Cited by 841 · cited 1×
“Alternatively, RAS activation/dependency/ addiction has been shown to anti-correlate with EMT [19].”
BackgroundBiological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes
Desmedt, C., Haibe-Kains, B., Wirapati, P., Buyse, M., Larsimont, D., Bontempi, G., Delorenzi, M., Piccart, M., & Sotiriou, C. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4756 · Cited by 828 · cited 1×
“Colon cancer, unlike breast cancer where luminal and basal “intrinsic” subtypes have been identified [7-13], or bladder cancer where intrinsic signatures of recurrence have been established [14,15], has yet to be classified by unsupervised, molecular profiling approaches.”
BackgroundSmith, J. J., Deane, N. G., Wu, F., Merchant, N. B., Zhang, B., Jiang, A., Lu, P., Johnson, J. C., Schmidt, C., Bailey, C. E., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.11.005 · Cited by 716 · cited 1×
“poor prognosis patient populations [2-6].”
Self-citationGene Expression Profiles and Molecular Markers To Predict Recurrence of Dukes' B Colon Cancer
Wang, Y., Jatkoe, T., Zhang, Y., Mutch, M. G., Talantov, D., Jiang, J., McLeod, H. L., & Atkins, D. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.186 · Cited by 460 · cited 1×
“poor prognosis patient populations [2-6].”
Cited by
The consensus molecular subtypes of colorectal cancer
Guinney, J., Dienstmann, R., Wang, X., de Reyniès, A., Schlicker, A., Soneson, C., Marisa, L., Roepman, P., Nyamundanda, G., Angelino, P., et al. (2015) · Nature Medicine · doi:10.1038/nm.3967 · Cited by 5,170
Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes
Cristescu, R., Lee, J., Nebozhyn, M., Kim, K.-M., Ting, J. C., Wong, S. S., Liu, J., Yue, Y. G., Wang, J., Yu, K., et al. (2015) · Nature Medicine · doi:10.1038/nm.3850 · Cited by 2,223
Self-citationProteogenomic characterization of human colon and rectal cancer
CPTAC, T. N., Zhang, B., Wang, J., Wang, X., Zhu, J., Liu, Q., Shi, Z., Chambers, M. C., Zimmerman, L. J., Shaddox, K. F., et al. (2014) · Nature · doi:10.1038/nature13438 · Cited by 1,462
Tan, T. Z., Miow, Q. H., Miki, Y., Noda, T., Mori, S., Huang, R. Y., & Thiery, J. P. (2014) · EMBO Molecular Medicine · doi:10.15252/emmm.201404208 · Cited by 792
“Although many reports have associated the EMT status with survival (Witta et al , 2006; Arumugam et al , 2009; Hrstka et al , 2010; Sethi et al , 2010; Loboda et al , 2011; Cieply et al , 2012; Byers et al , 2013; Marchini et al , 2013), our EMT scoring does not wholly support these findings.”
Stromal contribution to the colorectal cancer transcriptome
Isella, C., Terrasi, A., Bellomo, S. E., Petti, C., Galatola, G., Muratore, A., Mellano, A., Senetta, R., Cassenti, A., Sonetto, C., et al. (2015) · Nature Genetics · doi:10.1038/ng.3224 · Cited by 640
Metadata
- Authors
- Loboda, A., Nebozhyn, M. V., Watters, J. W., Buser, C. A., Shaw, P. M., Huang, P. S., Van't Veer, L., Tollenaar, R. A., Jackson, D. B., Agrawal, D., Dai, H., & Yeatman, T. J.
- Affiliations
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Leiden University Medical Center (NL)
- Moffitt Cancer Center (US)
- Corresponding author
- Yeatman, Timothy J
- ORCID
- Venue
- BMC Medical Genomics
- Published
- 2011-01-20
- Volume
- 4
- Issue
- 1
- Pages
- 9-9
- ISSN
- 1755-8794 (ISSN-L)
- PMC
- PMC3032646
- OpenAlex
- W1998558839
- Cited by
- 274
- References
- 32
- Citations by year
- 2026: 3 · 2025: 10 · 2024: 7 · 2023: 21 · 2022: 12 · 2021: 21 · 2020: 22 · 2019: 21 · 2018: 27 · 2017: 18 · 2016: 24 · 2015: 24 · 2014: 26 · 2013: 14 · 2012: 20
- FWCI
- 8.32
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- BMC Medical Genomics (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Leiden Repository (Leiden University) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Florida Department of Health
- National Institutes of Health (08BR-02)
- National Cancer Institute (CA112215, R01CA112215, 08BR-02)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene expression and cancer classification
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
- Keywords
- colon cancer, epithelial-mesenchymal transition, molecular subtypes, gene expression signatures, principal component analysis, microRNA, miR-200 family, recurrence, tumor progression, gene expression profiling
- MeSH terms
- Colonic Neoplasms, Humans, Recurrence, Vimentin, Disease Progression, Gene Expression Profiling, Principal Component Analysis, Cell Line, Tumor, Epithelial-Mesenchymal Transition
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: EMT is the dominant program in human colon cancer. https://app.cochat.ai/papers/10.1186/1755-8794-4-9
- The paper
- Loboda, A., Nebozhyn, M. V., Watters, J. W., Buser, C. A., Shaw, P. M., Huang, P. S., Van't Veer, L., Tollenaar, R. A., Jackson, D. B., Agrawal, D., Dai, H., & Yeatman, T. J. (2011). EMT is the dominant program in human colon cancer. BMC Medical Genomics. https://doi.org/10.1186/1755-8794-4-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.